FORT LAUDERDALE, Fla. — Pangea Pharmaceuticals has launched Sdamlo, a new formulation of amlodipine designed to simplify dosing and administration for patients who have difficulty taking traditional tablet medications.
The company said Sdamlo is the first FDA-approved amlodipine powder for oral solution, offering a unit-dose format intended to improve precision and ease of use across a range of patient populations, including children, older adults, and individuals with swallowing difficulties.
Amlodipine is widely prescribed for hypertension and other cardiovascular conditions, but standard tablets and some liquid formulations can be difficult for certain patients to use. Sdamlo is designed to address those challenges by eliminating the need to swallow pills and reducing preparation steps for caregivers and healthcare providers.
“Sdamlo reflects our commitment to creating better products from proven molecules and bringing them to market in a way that always puts patients first,” said Tony LaViola, CEO and Co-Founder of Pangea Pharmaceuticals. “We are focused on identifying meaningful gaps in care and delivering solutions that improve access, simplify administration, and support better outcomes. This launch is an important step as we continue to build a differentiated portfolio of life-enhancing products.”
The product is particularly suited for patients who are tube-fed or require enteral delivery, where crushing tablets can lead to dosing inconsistencies or complications. Its ready-to-administer format allows for more consistent dosing and reduces the risk of errors, the company said.
Sdamlo is produced using a freeze-drying process designed to improve stability and ensure uniform distribution of the active ingredient. The formulation is alcohol-free, preservative-free, and does not require refrigeration, making it suitable for use in hospitals, long-term care facilities, and other institutional settings.
The drug is being commercialized in partnership with Brillian Pharma, which developed the underlying formulation technology.
“We are proud to partner with Pangea Pharmaceuticals on the U.S. commercialization of Sdamlo, a product based on Brillian’s proprietary platform technology,” said Dr. Nolan Wang, Co-Founder and Chief Technology Officer of Brillian Pharma. “This collaboration reflects a shared commitment to advancing differentiated formulations of widely prescribed therapies while addressing challenges associated with traditional solid oral dosage forms. Sdamlo provides a more flexible option for patients who have difficulty swallowing, including pediatric and geriatric populations.”
Pangea said the launch marks an early step in building a broader portfolio of reformulated medicines aimed at improving patient access and adherence. The company plans to introduce Sdamlo in multiple strengths, with initial availability beginning in March and additional options expected in the coming months.
